



## SCIENTIFIC PROGRAMME

### PRELIMINARY PROGRAMME

Friday 28th June	
15.00-16.30	Registration
16.30-17.30	Local Language Session supported by ISCP Italia Management of Stroke: the guidelines and how to implement them M. Volterrani (Rome)
17.30-18.00	Discussion on implementation of guidelines
Saturday 29th June	
08.30	Opening remarks J.C. Kaski (London), President, ISCP
08.40	Welcome M. Volterrani, President of Local Organising Committee
<b>Session 1 - Cardiovascular Disease Prevention - Pharmacological Strategies</b> Chairs: F. Crea (Rome), Z. Fras (Ljubljana) and K. Hasegawa (Kyoto)	
08.45	Cardiovascular disease prevention beyond statins J. McNeil (Melbourne)
09.05	HDL- Still a therapeutic target? L. Badimon (Barcelona)
09.25	Statins trigger diabetes: clinical implications J.C. Kaski (London)
09.45	Fibrates and niacin: Any place in clinical practice? A. Wierzbicki (London)
10.05	Discussion: Cardiovascular Disease Prevention
<b>Session 2 - Cardiovascular Therapy: Expert Opinion</b> Chairs: A. Oto (Ankara), F. Romeo (Rome) and G. Rosano (Rome)	
10.20	Cardiovascular drug therapy in pregnancy: what to use and what to avoid? D. Adamson (Coventry)
10.40	New anticoagulants in AF - Pros and Cons Y. Rozenman (Tel Aviv)
11.00	Cardioprotection with antidiabetic drugs. Myth or reality? F. Pelliccia (Rome)
11.20	Discussion: Cardiovascular Drug Therapy
11.35	Coffee break

<b>Session 3 - Pharmacotherapy in Angina Pectoris</b>	
Chairs: A Goudev (Sofia) and J.C. Kaski (London)	
12.00	Ivabradine, Trimetazidine and beyond M. Marzilli (Pisa)
12.20	Interventional vs. medical treatment for stable angina P. Avanzas (Oviedo)
12.40	Pharmacotherapy for microvascular angina P. Ong (Stuttgart)
13.00	Discussion on treatment of Angina Pectoris
13.15	Interactive Lunch Seminar: Understanding cardiovascular comorbidities in COPD patients (Panel discussion)
<b>Session 4 - Expert Opinion in pharmacotherapy: from evidence based guidelines to real life practice</b>	
Chairs: F. Martinez (Cordoba) and D. Tziakas (Alexandroupolis)	
14.15	Combination therapy in hypertension: a sensible option? S. Taddei (Pisa)
14.35	Are ACE-I and ARBs interchangeable? P. Perrone-Filardi (Napoli)
14.55	The Polypill: Therapeutic panacea? C. Torp-Pedersen (Copenhagen)
15.15	Any role for beta blockers in hypertension? T. Kahan (Stockholm)
15.35	The role of ivabradine L. Tavazzi (Cotignola)
15.55	Discussion on Pharmacotherapy in practice
16.30	Coffee break
17.00	Low-dose aspirin in the prevention of atherothrombosis and cancer: is platelet inhibition a shared mechanism of action C. Patrono (Rome)
17.30	Local Language Symposium: Iperuricemia cronica con e senza deposito di urato e rischio cardiovascolare: Progetto Cristal G. Desideri (L'Aquila) Con il contributo non condizionato di MENARINI
18.30	End of Day 1 Sessions
Sunday 30th June	
<b>Session 1 - HOW TO...?</b>	
Chairs: A. Bayes de Luna (Barcelona), J. Camm (London) and D. Cokkinos (Athens)	
08.30	...Use NSAIDs safely in CAD patients? J. Tamargo (Madrid)
08.50	...Manage atrial fibrillation in 2013? G.A. Dan (Bucharest)
09.10	...Prevent stroke in patients with atrial fibrillation? A. Martinez Rubio (Barcelona)
9.30 -9.50	Summary Panel

<b>Session 2 - DEBATE</b>	
<b>All antiplatelets offer similar benefits in the management of ACS patients - Are the current guidelines wrong?</b>	
Chairs: A. Gallino (Bellinzona) and M Volterrani (Rome)	
10.00	For - A. Ferro (London)
10.20	Against - M. Tubaro (Rome)
10.40	Conclusion M. Volterrani (Rome)
<b>Session 3</b>	
10.50 - 11.30	Coffee and moderated poster session
<b>Session 4 - HEART FAILURE</b>	
Chair: K. Hasegawa (Kyoto) and F. Martinez (Cordoba)	
11.30	Old agents with new mechanisms or new agents with new targets: where is the best evidence? F. Martinez (Cordoba)
11.50	Drugs for AF in patients with heart failure J. Camm (London)
12.10	Management of acute decompensated HF: Why and where have we failed? A. Coats (Melbourne / Warwick)
12.30	Discussion on Pharmacotherapy e Haert Failure
13.15	Lunch and Posters
14.15	Young Investigator Award- Presentation of prizes J.C. Kaski (London) and M. Volterrani (Rome)
	Concluding remarks J.C. Kaski (London), G.A. Dan (Bucharest) and M. Volterrani (Rome)
15.00	End of Day 2 Sessions